In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Experimenting With New Pricing Models In Oncology

Executive Summary

Cancer drug prices are unsustainable and creative approaches are needed, Roche’s COO Daniel O’Day says. The firm’s moves into emerging markets are a lab for new methods, though the real test will come as the more expensive drugs are used in combination.

Advertisement

Related Content

Biopharma In 2013: A Rising Tide
The Cancer Trap
Avastin Takes One Step Forward, One Step Back At ASCO
NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line
Many New Oncology Drugs In 2012, With Prices That Test The Limits
ASCO Data Support Roche’s Grand Plan For Non-Stop Avastin Treatment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel